Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder

Objectıves. Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications. Our purpose in this study is to investigate efficacy, safety and tolerability of combined methylphenidate and atomoxetine pharmacotherapy. Methods. We included 1...

Full description

Saved in:

Bibliographic Details
Published in:	The world journal of biological psychiatry Vol. 16; no. 8; pp. 619 - 624
Main Authors:	Ozbaran, Burcu, Kose, Sezen, Yuzuguldu, Onur, Atar, Burcu, Aydin, Cahide
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 17-11-2015
Subjects:	Adolescent atomoxetine Atomoxetine Hydrochloride - adverse effects Atomoxetine Hydrochloride - therapeutic use Attention Deficit Disorder with Hyperactivity - drug therapy attention deficit hyperactivity disorder Central Nervous System Stimulants - adverse effects Central Nervous System Stimulants - therapeutic use Child combined therapy Diagnostic and Statistical Manual of Mental Disorders Drug Therapy, Combination Female Headache - etiology Humans Male methylphenidate Methylphenidate - adverse effects Methylphenidate - therapeutic use pharmacotherapy Psychiatric Status Rating Scales Severity of Illness Index Treatment Outcome combined therapy methylphenidate attention deficit hyperactivity disorder atomoxetine pharmacotherapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objectıves. Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications. Our purpose in this study is to investigate efficacy, safety and tolerability of combined methylphenidate and atomoxetine pharmacotherapy. Methods. We included 12 patients of the 824 patients with ADHD using methylphenidate and atomoxetine combined therapy between the years 2010 and 2014. Kiddie-SADS, Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale, Child Behavior Checklist, Clinic Global Impression Scale Severity and Impression (CGIS-S-I) scales were used. Results. Patients were between the ages of 7 and 17 years. Before combined pharmacotherapy the CGIS-S score mean was 5.08. Mean CGIS-S score after the combined pharmacotherapy was 3.08 (P = 0.03; -2,980). The most common side effects were irritability (n = 5, 41.6%), appetite reduction (n = 3, 25%), palpitations (n = 2, 16.7%), headache (n = 1, 8.3%). Conclusıons. Nine of these 12 patients showed significant improvement in their symptoms, combined therapy enhanced the effectiveness of monotherapy.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1562-2975 1814-1412
DOI:	10.3109/15622975.2015.1051109